TrialEBioMedicine2016

Safety and Immunogenicity of the Recombinant BCG Vaccine AERAS-422 in Healthy BCG-naïve Adults: A Randomized, Active-controlled, First-in-human Phase 1 Trial.

Daniel F Hoft et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.